Chromadex (NASDAQ:CDXC) has been given a $8.00 price target by equities research analysts at HC Wainwright in a report released on Friday. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 50.38% from the company’s current price.
Several other analysts also recently issued reports on the company. BidaskClub raised Chromadex from a “sell” rating to a “hold” rating in a research note on Friday. ValuEngine upgraded Chromadex from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Zacks Investment Research cut Chromadex from a “buy” rating to a “hold” rating in a report on Wednesday, November 29th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $7.50.
Chromadex (CDXC) traded up $0.01 on Friday, hitting $5.32. The company’s stock had a trading volume of 162,030 shares, compared to its average volume of 543,739. Chromadex has a 1 year low of $2.26 and a 1 year high of $7.24. The firm has a market cap of $259.50, a P/E ratio of -37.00 and a beta of 1.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 4.12.
In related news, CEO Frank L. Jaksch, Jr. sold 58,400 shares of Chromadex stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $6.19, for a total transaction of $361,496.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Frank L. Jaksch, Jr. sold 28,379 shares of Chromadex stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $6.52, for a total value of $185,031.08. The disclosure for this sale can be found here. Company insiders own 11.59% of the company’s stock.
A number of institutional investors have recently bought and sold shares of CDXC. Goldman Sachs Group Inc. grew its holdings in Chromadex by 870.6% during the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after purchasing an additional 163,817 shares during the period. Thompson Davis & CO. Inc. acquired a new stake in Chromadex during the third quarter worth approximately $128,000. Granite Investment Partners LLC lifted its position in Chromadex by 5.7% during the third quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after acquiring an additional 13,599 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Chromadex during the fourth quarter worth approximately $250,000. Finally, Cetera Advisor Networks LLC acquired a new stake in Chromadex during the fourth quarter worth approximately $147,000. Institutional investors and hedge funds own 5.87% of the company’s stock.
Chromadex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.